Average Co-Inventor Count = 7.59
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Janssen Pharmaceutica Nv (13 from 2,078 patents)
2. Asterand UK Limited (10 from 10 patents)
3. Cancer Research Technology Limited (6 from 262 patents)
4. Pulmagen Therapeutics (asthma) Limited (4 from 4 patents)
5. Corcept Therapeutics Incorporated (3 from 130 patents)
6. C4x Discovery Limited (1 from 6 patents)
7. Pharmagene Laboratories Limited (1 from 4 patents)
8. Gboo1, Inc. (1 from 1 patent)
9. Argenta Discovery Limited (2 patents)
10. Pulmagen Therapeutics Limited (0 patent)
39 patents:
1. 12098148 - Therapeutic compounds
2. 11680068 - Compounds useful as RET inhibitors
3. 11661423 - Heterocyclic compounds as RET kinase inhibitors
4. 11548896 - Heterocyclic compounds as RET kinase inhibitors
5. 11352361 - Compounds useful as RET inhibitors
6. 11236084 - Substituted azaindoline derivatives as NIK inhibitors
7. 11186589 - Cyanoindoline derivatives as NIK inhibitors
8. 11180487 - Substituted cyanoindoline derivatives as NIK inhibitors
9. 11136311 - Heteroaromatic derivatives as NIK inhibitors
10. 11001569 - 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
11. 10954241 - Heterocyclic compounds as ret kinase inhibitors
12. 10844067 - Heterocyclic compounds as RET kinase inhibitors
13. 10822342 - Pyrazolopyrimidine derivatives as NIK inhibitors
14. 10626089 - Quinoline derivative in crystal form
15. 10323045 - Thienopyrimidine derivatives as NIK inhibitors